A decade of controversy: Balancing policy with evidence in the regulation of prescription Drug advertising

Dominick L. Frosch, David Grande, Derjung M. Tarn, Richard L Kravitz

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the Food and Drug Administration in 1997. We reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA. This advertising has some benefits, but significant risks are evident as well, magnified by the prominence of DTCA in populationlevel health communications. To minimize potential harm and maximize the benefits of DTCA for population health, the quality and quantity of information should be improved to enable consumers to better self-identify whether treatment is indicated, more realistically appraise the benefits, and better attend to the risks associated with prescription drugs. We propose guidelines for improving the utility of prescription drug advertis ing.

Original languageEnglish (US)
Pages (from-to)24-32
Number of pages9
JournalAmerican Journal of Public Health
Volume100
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Prescription Drugs
Health Communication
United States Food and Drug Administration
Guidelines
Direct-to-Consumer Advertising
Health
Population

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

A decade of controversy : Balancing policy with evidence in the regulation of prescription Drug advertising. / Frosch, Dominick L.; Grande, David; Tarn, Derjung M.; Kravitz, Richard L.

In: American Journal of Public Health, Vol. 100, No. 1, 01.01.2010, p. 24-32.

Research output: Contribution to journalArticle

@article{0703806fe3b9471499accfeb9920c0c2,
title = "A decade of controversy: Balancing policy with evidence in the regulation of prescription Drug advertising",
abstract = "Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the Food and Drug Administration in 1997. We reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA. This advertising has some benefits, but significant risks are evident as well, magnified by the prominence of DTCA in populationlevel health communications. To minimize potential harm and maximize the benefits of DTCA for population health, the quality and quantity of information should be improved to enable consumers to better self-identify whether treatment is indicated, more realistically appraise the benefits, and better attend to the risks associated with prescription drugs. We propose guidelines for improving the utility of prescription drug advertis ing.",
author = "Frosch, {Dominick L.} and David Grande and Tarn, {Derjung M.} and Kravitz, {Richard L}",
year = "2010",
month = "1",
day = "1",
doi = "10.2105/AJPH.2008.153767",
language = "English (US)",
volume = "100",
pages = "24--32",
journal = "American Journal of Public Health",
issn = "0090-0036",
publisher = "American Public Health Association Inc.",
number = "1",

}

TY - JOUR

T1 - A decade of controversy

T2 - Balancing policy with evidence in the regulation of prescription Drug advertising

AU - Frosch, Dominick L.

AU - Grande, David

AU - Tarn, Derjung M.

AU - Kravitz, Richard L

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the Food and Drug Administration in 1997. We reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA. This advertising has some benefits, but significant risks are evident as well, magnified by the prominence of DTCA in populationlevel health communications. To minimize potential harm and maximize the benefits of DTCA for population health, the quality and quantity of information should be improved to enable consumers to better self-identify whether treatment is indicated, more realistically appraise the benefits, and better attend to the risks associated with prescription drugs. We propose guidelines for improving the utility of prescription drug advertis ing.

AB - Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the Food and Drug Administration in 1997. We reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA. This advertising has some benefits, but significant risks are evident as well, magnified by the prominence of DTCA in populationlevel health communications. To minimize potential harm and maximize the benefits of DTCA for population health, the quality and quantity of information should be improved to enable consumers to better self-identify whether treatment is indicated, more realistically appraise the benefits, and better attend to the risks associated with prescription drugs. We propose guidelines for improving the utility of prescription drug advertis ing.

UR - http://www.scopus.com/inward/record.url?scp=74049146377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049146377&partnerID=8YFLogxK

U2 - 10.2105/AJPH.2008.153767

DO - 10.2105/AJPH.2008.153767

M3 - Article

C2 - 19910354

AN - SCOPUS:74049146377

VL - 100

SP - 24

EP - 32

JO - American Journal of Public Health

JF - American Journal of Public Health

SN - 0090-0036

IS - 1

ER -